United States: Circuit Affirms Exclusion From Federal Health Care Programs Under "Responsible Corporate Officer" Doctrine: Companies And Executives Beware Of An Emboldened Department Of Justice And HHS Office Of Inspector General

Last Updated: September 26 2012
Article by Adam S. Lurie and Brian T. McGovern

Most Read Contributor in United States, December 2018

The authors analyze a recent federal circuit court decision that, they believe, may lead the Department of Justice and the Department of Health and Human Services to feel more emboldened than ever to pursue aggressively "responsible corporate officers" more than they have so far.

On July 27, 2012, in the closely watched case of Michael Friedman, et al. v. Kathleen Sebelius, et al., the United States Court of Appeals for the D.C. Circuit held that pharmaceutical corporate executives found guilty of misdemeanor "misbranding" under the "responsible corporate officer doctrine" ("RCO doctrine") had committed a "misdemeanor relating to fraud" pursuant to 42 U.S.C. § 1320a-7(b)(1), thereby subjecting them to exclusion from federal health care programs.

A s described further below, before the D.C. Circuit the executives argued that misdemeanor misbranding did not relate to fraud because, among other reasons, they were convicted under the RCO doctrine, which is a strict liability offense that does not require proof of intent. The circuit court rejected their arguments, finding instead that 42 U.S.C. § 1320a-7(b)(1) "authorizes the [Secretary of Health and Human Services ("HHS")] to exclude from participation in federal health care programs an individual convicted of a misdemeanor if the conduct underlying that conviction is factually related to fraud."

This is a significant decision because it confirms — subject to potential review by the U.S. Supreme Court — what many in the life sciences and health care industry have feared. Namely, the Office of Inspector General ("OIG") within HHS can exclude pharmaceutical, medical device, and other health care corporate and marketing executives who did not personally commit or condone fraud, but instead merely failed to prevent misbranding or other misdemeanors arguably "related to" fraud, such as adulteration.

Importantly, exclusion from federal health programs makes it nearly impossible for such executives to engage in any work — during the period of the exclusion — that may involve Medicaid or Medicare reimbursement or other federal health-care related contracting or services. For many, such a remedy could spell the end of their careers.

As described further below, it is also significant because the Department of Justice ("DOJ"), in concert with the Food and Drug Administration ("FDA") and the OIG, has recently turned to the RCO doctrine with greater frequency. In light of the Friedman decision, we anticipate that this trend will continue and will likely increase. More broadly, there has been increased clamor for regulators and prosecutors to more aggressively pursue senior executives for corporate wrongdoing and to hold them personally liable, on the theory that prosecuting and fining the corporation alone is insufficient to prevent or deter corporate crimes and regulatory noncompliance.

Thus, perhaps now more than ever, pharmaceutical, medical device and other health care industry executives must be particularly vigilant against their RCO exposure.

The RCO Doctrine

Under the RCO doctrine, a corporate executive may be held criminally liable for a company's criminal violations of the Food, Drug, and Cosmetic Act ("FDCA"), if the executive's acts or omissions facilitated the FDCA violation — whether or not the executive knew of the company's criminal violations. Thus, criminal liability under the RCO doctrine extends not only to corporate agents who themselves committed the criminal act, but also to those who, by virtue of their managerial positions or other similar relation to the actor, could be deemed "responsible" for its commission.

Accordingly, the RCO doctrine is unique in criminal law — unlike most criminal laws, which require a defendant to have committed a wrongful act with criminal intent, the RCO doctrine does not require proof of such intent. Thus, under the doctrine, a corporate officer can be held criminally liable even for a subordinate employee's criminal activity, where the officer did not participate in, or even know anything about, the wrongful conduct.

The RCO doctrine has existed for many years, and has been recognized and upheld by the U.S. Supreme Court in two leading cases involving the FDCA: United States v. Dotterweich (involving misdemeanor misbranding of drugs)1 and United States v. Park (misdemeanor adulteration of food because of rats in a warehouse).2 While the RCO doctrine is commonly associated with FDCA prosecutions, federal and/or state courts have also approved its use in other contexts including in matters involving violations of the securities, antitrust, environmental and consumer fraud laws.

Michael Friedman, et al. v. Kathleen Sebelius, et al.

The facts in Friedman are straightforward: the Purdue Frederick Company had been convicted in May 2007 of fraudulent misbranding — a felony — involving the drug known as Oxycontin. Three of its executives entered into plea agreements and were convicted under the RCO doctrine of misdemeanor misbranding of a drug, for failing to prevent the fraudulent marketing of Oxycontin.

Based upon their convictions, and after all administrative appeals had been exhausted, the Secretary of HHS ultimately excluded them from participation in federal health care programs for 12 years.

The executives sought a reversal of their 12-year exclusion in federal court, but the district court upheld the exclusion decision. Accordingly, the executives appealed both the exclusion and its length to the D.C. Circuit.

On appeal, the executives argued that Section 1320a-7(b)(1) did not authorize the exclusion because misdemeanor misbranding is not a "misdemeanor relating to fraud." In this regard, the executives noted that misdemeanor misbranding does not necessarily require a "culpable mental state because a conviction for the offense may be, and in this case was, predicated upon the responsible corporate officer doctrine, which entails strict liability." The circuit court, however, rejected this argument, concluding that the Secretary of HHS may appropriately examine the circumstances underlying the RCO misdemeanor conviction to determine if it was "related to" fraud:

[T]he text, structure, and purpose of the statute, viz. to protect Federal health care programs from financial harm wrought by untrustworthy providers, all indicate the Secretary's circumstance approach is proper; i.e., the statute authorizes exclusion of an individual whose conviction was for conduct factually related to fraud.

The circuit court went on to construe the meaning of "related to" expansively to encompass an executive's misdemeanor offense factually connected with a fraud committed by others employed by the corporation. The circuit court reasoned that this phrase was extremely broad and "[r]ather than referring only to generic misdemeanor offenses that share all the 'core elements' of fraud, the capacious phrase includes any criminal conduct that has a factual 'connection with' fraud." In light of the circuit court's broad construction of this language and its analysis of other aspects of the statute, the circuit court concluded that:

Their convictions for misdemeanor misbranding were predicated upon the company they led having pleaded guilty to fraudulently misbranding a drug and they admitted having 'responsibility and authority either to prevent in the first instance or to promptly correct' that fraud; they did neither. Accordingly, section 1320a-7(b)(1)(A) authorized the Secretary to exclude them for a time from participation in Federal health care programs.

12-Year Exclusion Unsupported by Record

With respect to the length of the exclusion, however, the circuit court agreed with the executives that the 12-year exclusion was not adequately supported in the record, and was therefore "arbitrary and capricious." Specifically, HHS had not adequately explained why the Secretary had excluded these executives for as long as 12 years, while previous executives excluded on the basis of a misdemeanor had all received shorter exclusion periods. At the same time, the circuit court did not conclude that a 12 year exclusion was necessarily excessive:

We do not suggest the Appellant's exclusion for 12 years based upon a conviction for misdemeanor misbranding might not be justifiable; we express no opinion on that question.

Rather, the D.C. Circuit ordered the district court to remand the issue to HHS for further fact finding consistent with its opinion.

In creased Reliance on the RCO Doctrine: What Should Companies An d Executives Do Now?

In the past several years, senior officials at the DOJ, FDA and OIG have stated publicly their agencies' intent to pursue RCO cases involving FDCA violations and other misconduct. For example, in 2009, then Assistant Attorney General of the Civil Division Tony West said the Justice Department would use the doctrine with greater frequency to combat health care fraud; and in 2010, FDA Commissioner Margaret Hamburg made a similar announcement.

Recent prosecutions and regulatory actions demonstrate that the government is determined to live up to its promise of stepped-up enforcement. For instance, in April 2012, Gary Osborn and his corporation, ApothéCure Inc., pleaded guilty in connection with ApothéCure's interstate shipment of two lots of misbranded colchicine injectable solution that led to the deaths of three people in the Pacific Northwest. Regarding Osborn's guilty plea, DOJ Acting Assistant Attorney General of the Civil Division Stuart Delery stated that the plea "shows that the Department of Justice will enforce the [FDCA] against responsible corporate officers of companies that fail to control the quality of their products."

Given the DOJ and OIG's well publicized focus on combatting health care fraud, pharmaceutical, medical device and other health care entities whose executives face potential RCO doctrine liability must focus their compliance efforts to guard against RCO liability. In connection with any fraud prosecution or enforcement action against the corporation, executives will have to carefully weigh the collateral consequences — especially exclusion — of entering into a misdemeanor guilty plea, should the authorities look to hold the executive criminally liable under the RCO doctrine. More proactively, however, executives can try to protect themselves from RCO exposure in several ways, such ways as the following:

  • Participating in compliance training;
  • Adhering to the company's compliance program;
  • Ensuring that the company conducts regular evaluations and audits of employees whose duties could give rise to violations;
  • Ensuring that such employees receive compliance training and adhere to the company's compliance program;
  • Ensuring that employees who report directly to the executives are instructed to, and made accountable for, affirmatively and timely reporting to them any suspected serious misconduct or non-compliance within the departments or divisions those employees oversee, and that in turn similar "reporting-up" obligations are imposed within each division or department and throughout the reporting chain; and
  • Regularly evaluating the effectiveness of the company's compliance program, and whether it adequately seeks to identify and address potential areas of RCO liability.

Failure to follow these and other steps to protect against RCO liability could increase the risk not only of prosecution, but also of exclusion from federal health care programs, as we saw in Friedman. Indeed, in light of the circuit court's decision in Friedman, DOJ and HHS may feel more emboldened than ever to pursue aggressively RCO actions and exclusions.

Originally published in Financial Fraud Law Report , October 2012

Footnotes

1. 320 U.S. 277 (1943).

2. 421 U.S. 658 (1975).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions